List view / Grid view
Full results from the “first Phase III study of a…
Full results from the “first Phase III study of a disease-modifying therapy to replicate the positive clinical results observed in a previous study” have been published in JAMA.
A complete response letter for Eli Lilly's accelerated approval submission…
A complete response letter for Eli Lilly's accelerated approval submission of donanemab for early Alzheimer's has been issued by the US Food and Drug Administration (FDA).
Eli Lilly and Company have announced executive leadership changes and…
Eli Lilly and Company have announced executive leadership changes and the creation of neuroscience and immunology business units.
Priority review has been given to the NDA for selpercatinib…
Priority review has been given to the NDA for selpercatinib to treat advanced RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.
Results did not confirm the clinical benefit of Lartruvo in…
Results did not confirm the clinical benefit of Lartruvo in combination with doxorubicin compared to doxorubicin alone…
